BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...BAER-101 (AZD7325). AZ, which granted Baergic exclusive, worldwide rights to the positive allosteric modulator of GABRA2...
...begin a pivotal trial in undifferentiated pleomorphic sarcoma in 2020. Targets: JAK - Janus kinase; GABRA2...
...Writer KN035, 3D-2-02-0015 Theravance Biopharma Inc. Pfizer Inc. Tracon Pharmaceuticals Inc. 3D Medicines Corp. Fortress Biotech Inc. AstraZeneca plc Progenics Pharmaceuticals Inc. Janus kinase (JAK) GABA A receptor alpha 2 (GABRA2) GABA...
BioCentury | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

Label expansion for AZ’s Calquence under Project ORBIS FDA approved an sNDA for Calquence acalabrutinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat chronic lymphocytic leukemia and small lymphocytic leukemia under the agency’s Real-Time Oncology Review...
BioCentury | Apr 11, 2019
Clinical News

Cerevel's GABA A modulator reduces photosensitivity in epilepsy patients

...treat patients with photosensitive epilepsy. CVL-865 (formerly PF-06372865) is a GABA A receptor α 2 (GABRA2... funding from Bain Capital (see "Springing into Cerevel" ). Chris Lieu, Staff Writer Cerevel Therapeutics LLC Pfizer Inc. GABA A receptor alpha 2 (GABRA2) GABA...
BioCentury | Oct 26, 2018

Springing into Cerevel

...Ib-ready muscarinic acetylcholine receptor M4 (CHRM4; HM4) agonist to treat psychosis and a Phase II-ready GABA A receptor alpha 2 (GABRA2)/GABRA3...
...the space (see “Pfizer Plugs Back In” ). Sandi Wong, Staff Writer Bain Capital Pfizer Inc. Dopamine D1 receptor (DRD1) GABA A receptor alpha 2 (GABRA2) GABA...
BioCentury | Nov 16, 2017
Translation in Brief

Lighting up the DYRK

Kyoto University researchers have described a DYRK1A inhibitor that could treat neuronal deficits in Down syndrome with fewer side effects than other inhibitors of the kinase -- but neurology company NeuroNascent Inc. suggests the safety...
BioCentury | Sep 19, 2017
Distillery Therapeutics


INDICATION: Schizophrenia Mouse studies suggest inhibiting GABRA1 could help treat schizophrenia. In a mouse model of schizophrenia, injection into the nucleus accumbens (NAC) core of an adeno-associated viral (AAV) vector encoding shRNA targeting GABRA1 decreased...
BioCentury | Aug 31, 2017
Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience , a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in some...
BioCentury | Feb 25, 2016
Distillery Therapeutics

Therapeutics: GABA A receptor β3 (GABRA3)

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting GABRA3 could help treat breast cancer. In patient samples, levels of GABRA3 were higher in metastatic tumors than in primary tumors or normal breast...
BioCentury | Jan 7, 2016
Distillery Techniques

Techniques: Mouse model of intellectual disability involving non-POU domain containing octamer-binding (NONO; NMT55) mutations

...Disease models GABA A receptor GABRA2 gephyrin (GPHN) non-POU domain containing octamer-binding NMT55 University of Zurich BC...
Items per page:
1 - 10 of 22